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Background: Hepatopulmonary syndrome (HPS) is characterized by advanced liver disease, hypoxemia and
intrapulmonary vascular dilatation (IPVD). The pathogenesis of HPS is not completely understood. Recent findings
have established the role of proliferation and phenotype differentiation of pulmonary microvascular endothelial
cells (PMVECs) in IPVD of HPS; the change in cytoskeletal proteins and their molecular mechanism play an essential
role in the proliferation, phenotype modulation and differentiation of PMVECs. However, little is known about the
relevance of cytoskeletal protein expression and its molecular mechanism in IPVD of HPS. In addition, ANX A1
protein has been identified as a key regulator in some important signaling pathways, which influences cytoskeletal
remodeling in many diseases, such as lung cancer, liver cancer, etc.
Methods: PMVECs were cultured from the normal rats and then divided into three groups(Ad-ANXA1-transfected
group, a non-transfected group, and an adenovirus empty vector group) and incubated by nomal rat serum or
hepatopulmonary syndrome rat serum respectively. mRNA level was evaluated by real time reverse transcription
polymerase chain reaction, and protein expression was detected by western blot. Cell proliferation was determined
by the MTT and thymidine incorporation assay.
Results: In this study, we found that the serum from a common bile duct ligation(CBDL) Rat model decreased the
expression levels of the ANX A1 mRNA and protein by at least two-fold in human PMVECs. We also found the
expression of cytoskeletal proteins (Destrin, a1-actin, and a1-tubulin) in PMVECs significantly increased. After
stimulating ANX A1 over-expression in PMVECs by adenovirus-mediated ANX A1 (Ad-ANXA1) transfection, we found
the expression levels of cytoskeletal proteins were significantly suppressed in PMVECs at all time points.
Additionally, we report here that serum from a CBDL Rat model increases the proliferation of PMVECs by nearly
two-fold and that over-expression of Ad-ANXA1 significantly inhibits HPS-rat-serum-induced PMVEC proliferation
(p <0.05). These findings suggest that the ANX A1 down-regulation of PMVEC proliferation in the presence of
HPS-rat-serum may be the major cause of aberrant dysregulation of cytoskeletal proteins (Destrin, a1-actin, and
a1-tubulin) and may, therefore, play a fundamental role in the proliferation and phenotype differentiation of
PMVECs in the PVD of HPS.
Conclusion: Finally, the fact that transfection with Ad-ANXA1 results in inhibition of the aberrant dysregulation of
cytoskeletal proteins and proliferation of PMVECs suggests a potential therapeutic effect on PVD of HPS.
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Hepatopulmonary syndrome (HPS) is classically defined
by a widened alveolar-arterial gradient at room tempe-
rature (>15 mmHg or >20 mmHg in patients >64 years
of age), with or without hypoxemia resulting from in-
trapulmonary vasodilatation (IPVD) in the presence of
hepatic dysfunction or portal hypertension [1]. HPS
occurs in at least 15% of patients with end-stage liver
disease but is thought to be widely underdiagnosed.
Mortality within a year of diagnosis is markedly increa-
sed in HPS patients with cirrhotic compared to patients
without cirrhotic. [2,3]. There is currently no effective
medical treatment for HPS. Liver transplantation (LT)
is considered the only dependable mode of therapy
for HPS [4,5]. The main reason for the absence of ef-
fective therapeutic measures is that the pathophysio-
logical mechanisms associated with HPS have not been
identified.
Although not yet completely clear, the pathogenesis of
HPS is believed to involve a number of factors. In par-
ticular, IPVD occurs in many cirrhotic patients and is
believed to contribute to pulmonary microvascular re-
modeling and arterial hypoxemia [5,6]. Thus, IPVD and
blunted hypoxic vasoconstriction were central to ventila-
tion-perfusion mismatching, leading to arterial hypox-
emia [7-9]. Currently, the hypotheses for explaining the
pathogenesis of IPVD remain speculative, despite the
various experimental studies that have been conducted.
Emphasis has been given to the roles that many cyto-
kines may play in pulmonary microcirculation and in the
genesis of IPVD [10]. Following liver damage, endothelin
(ET-1) produced in the liver migrates into pulmonary
circulation and appears to interact preferentially with
the ETB receptor, thereby promoting pulmonary vaso-
dilatation [11]. Analysis of a model for liver cirrhosis
and hyperdynamic circulation following common bile
duct ligation(CBDL) revealed greater hepatic production
and plasma circulation of ET-1, which is associated with
the development of IPVD [12]. In cases of liver cirrhosis,
the levels of tumor necrosis factor-alpha (TNF-α) also
increase, which contributes to the accumulation of mac-
rophages in the lumen of the pulmonary vessels. In turn,
these macrophages stimulate another NO-producing en-
zyme (induced nitric oxide synthase, iNOS), thereby trig-
gering IPVD [13]. These experimental findings regarding
the roles of ET-1, TNF-α and other cytokines in the de-
velopment of IPVD in pulmonary microvasculature may
contribute to understanding the physiopathology of HPS
in humans. However, treatment options aimed directly
at cytokines, such as inhaled NG-nitro-L-arginine me-
thyl ester (L-NAME), intravenous methylene blue, som-
atostatin, almitrine, indomethacin, norfloxacin, etc., have
been tested in HPS cases, but currently no treatment
offers satisfactory results for HPS reversion [13-17].Further studies have been demanded and might offer
a new approach to the therapeutic treatment of HPS.
Our previous data demonstrated that the proliferation
of PMVECs plays an important role in the development
of IPVD [18,19]. However, many signaling pathways,
such as PI3K-Akt, MLCK, TGF-β/Smads, and PKC/ERK,
are involved in the regulation of the differentiation or
proliferation of PMVECs. These signaling pathways
interact with each other, and blocking one pathway may
not be sufficient to reduce the incidence and develop-
ment of IPVD. The cytoskeleton is essential not only for
the maintenance of cell shape and motility but also for
the integration of cell signals that initiate and propagate
alterations in these cellular properties. Because cytoske-
letal proteins are very important in the proliferation and
differentiation of PMVECs, we hypothesize that regula-
ting the expression of cytoskeletal proteins may be a key
upstream target and provide a new approach to HPS
prevention and treatment. However, many uncertainties
exist in this research area, including the relationship
between cytoskeletal proteins and the proliferation or
differentiation of PMVECs in HPS and the molecular
mechanisms.
Annexin A1 (ANX A1) is a member of the calcium
and membrane-binding family and plays an essential role
in tumorigenesis and apoptosis. In recent years, there
have been accumulating data indicating a novel role for
ANX A1 in cell proliferation and migration. However,
the role of ANX A1 in CBDL-rat-serum-induced PMVEC
differentiation and proliferation has not been previously
described.
A well-established experimental model for hepatopul-
monary syndrome is biliary cirrhosis and portal hyper-
tension in rats induced by CBDL [8] and is the only
recognized model for the study of HPS [8].
The purpose of this work was to examine the role of
cytoskeletal proteins in PMVEC responses to serum
from the CBDL rat model and specifically to investigate
the role of ANX A1 in regulating the expression of cyto-
skeletal proteins and in the proliferation and differen-
tiation of PMVECs under CBDL-rat-serum conditions.
Our data showed that the expression of cytoskeletal
proteins and cell proliferation increased significantly fol-
lowing stimulation with CBDL rat serum. In addition,




The reagents used in the study included rabbit polyclo-
nal anti-rat ANXA1 antibody (NeoMarkers,USA), rab-
bit polyclonal anti- rat a1-actin antibody (NeoMarkers,
USA), rabbit polyclonal anti- rat a1-tubulin antibody
(NeoMarkers,USA), rabbit polyclonal anti-rat destrin
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generous gift from the Institute of Respiratory Diseases,
Xinqiao Hospital, Third Military Medical University), and
immunohistochemistry kits (Boster, China).CBDL rat model, cell culture, grouping of PMVECs and
Ad-ANXA1 transfection
All procedures performed on the rats were conducted
according to the guidelines from the National Institutes
of Health. The study protocol was approved by the
committee on Animal Research of Southwest Hospital.
Sprague Dawley rats (180–220 g body wt) were used in
this study. The CBDL rat model has been built success-
fully in our initial study. Details of the surgery and post-
surgical care were similar to the previous studies [8,20].
At PaO2 < 85 mm Hg, the blood serum of rats with
P(A-a)O2 > 18 mm Hg and pulmonary vasodilatation
(PVD) found on pathological sections was used for
this study. Serum was separated from CBDL blood sam-
ples (centrifugation at 2000 × g/min in a Gyria for 10 min
at 4°C) within 20 min of collection, was carefully handled
to avoid hemolysis, and was stored at −80°C.
PMVECs were isolated from the rat lung as previously
described [21]. Briefly, 2–5 g of rat peripheral tissue was
isolated from a normal SD rat. Lung tissue was rinsed in
10 mM phosphate-buffered saline (PBS, pH 7.4), finely
minced into small pieces and digested in 0.3% type II
collagenase (Sigma Chemical Co., Oakville, Ontario) for
45 min at 37°C with occasional agitation. The digested
suspension was filtered through 100 μm mesh, cen-
trifuged at 500 × g and washed twice in PBS. The cell
pellet was resuspended in binding buffer (2 μm Na-
citrated, 1.2 μM NaH2PO4H2O, 5.6 μM Na2HPO4,
138.6 μM NaCl, and 1% bovine serum albumin) and in-
cubated for 20 min at 4°C with magnetic microbeads
(Dynal Inc., Lake Success, NY) coated with anti-CD31
antibody. Cells bound to microbeads were magnetically
captured and washed 5 times with binding buffer.
Isolated cells were resuspended in 10% Endothelial
Growth Medium-2 (EGM-2, Cambrex Bio Science Inc.,
Walkersville, MD) and incubated for 8–12 h at 37°C
in 5% CO2/21% O2. The culture medium was changed
every three days to remove unattached cells. Seven to
10 days after seeding the cells, the fast growing fibro-
blasts in the flask were repeatedly removed mechanically
using the sharp end of a rubber rod under direct micros-
copy to allow visually identified PMVEC clusters to
grow. When the PMVECs proliferated to 50% conflu-
ence, they were harvested with trypsin-EDTA and were
re-purified with anti-CD31-coated magnetic microbeads
as previously described. PMVEC were seeded in a 25-cm
2 flask and passaged at a ratio of 1:3. PMVEC were used
for experiments at passages 2–3.Inoculated PMVECs of the same concentration (106/
cm2) were divided into an Ad-ANXA1-transfected group,
a non-transfected group, and an adenovirus empty vector
group. Culture conditions were defined as 21% O2 and 5%
CO2. When the cells covered 80% of the flask bottom, the
original serum was replaced with 0.1% fetal calf serum.
After 24 h of synchronous growth, the PMVECs were in-
cubated under 5% HPS rat serum or normal rat serum
conditions for 0 h (T1), 12 h (T2), and 24 h (T3). At 24 h
prior to treatment, Ad-ANXA1, at a multiplicity of infec-
tion (MOI) of 60, was added into the medium of the Ad-
ANXA1 transfection group. The flask of this group was
placed upside-down on an inverted immunofluorescence
microscope to observe the transfection efficiency.Real-time RT-PCR analysis
Total RNA was extracted at indicated time points using
the Tripure Isolation Reagent. Reverse transcription (RT)
was performed with 2 μg RNA, Oligo (dT)15 (Sangon,
China), dNTP (Sangon, China), and the reaction buffer
supplied with the M-MLV reverse transcriptase (Promega,
USA). The fluorescence intensity ratio of the target gene
to GAPDH was used as a measure of the relative gene
expression. Specific primer sequences were used for the
amplification of ANX A1 (forward primer: 50- TAAGCG
AAACAATGCACAGC −30; reverse primer: 50- CAAA
GCGTTCCGAAAATCTC −30; 331 bp) and GAPDH (for-
ward primer: 50-TGGAGTCCACTGGCGTCTTCAC-30;
reverse primers: 50-CATGAGGTCCACCAGCCCTGTT
G-30; 698 bp).Western blotting
Standard techniques were used to collect cells. Cells
were lysed in a buffer (0.5% Nonidet P-40, 10 mM Tris,
pH 7.4, 150 mM NaCl, 1 mM EDTA, and 1 mM
Na3VO4) containing a protease inhibitor (1 mM PMSF).
The BCA protein assay was used to quantify protein.
Equal quantities of protein were analyzed by sodium
dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-
PAGE). The protein was transferred to the PVDF mem-
branes. The membranes were blocked for 1 h using 5%
milk in Tris-buffered saline with 0.1% Tween. After
washing twice for 5 min each, the membranes were
incubated with primary antibody (1:1000 dilution) at
37°C for 1 h and then overnight at 4°C. The mem-
brane was washed twice with TBS, and then the bound
antibody was detected using the IgG-HRP secondary anti-
body (1:500 dilution) for 30 min. The membranes were
stained with diaminobenzidine, scanned, and stored using
a gel imaging system. The optical density of the immu-
noreactivity was measured and analyzed with an Alpha
Imager.
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After the cells of each group were digested, the solution of
each group was made into a cell suspension to count the
cell number. The cell concentration was adjusted to 2 ×
104/ml. Each group of cells was inoculated on a
96-well plate. The cells were cultured for 2 d prior to hyp-
oxic treatment, and 1 μCi 3H-TdR (1 μCi/well) was added
to each well 6 h prior to culture termination. The incorpor-
ation was stopped with cold PBS solution, and 0.25% tryp-
sin was added to digest the cells and separate them from
the cell wall. Cells were collected on a glass fiber filter with
a multi-head harvester. The cells were washed with physio-
logical saline 3 times, stabilized with 10% trichloroacetic
acid, decolorized with absolute ethanol, dried for 30 min at
80°C, transferred into scintillation fluid, and counted with
a liquid scintillation counter (counts/min, cpm).
MTT assay
Cells (103 - 104) were inoculated into each well of a
96-well plate. The plate was placed in 5% CO2 and cul-
tured for 24 h. Each group received the appropriate
treatment for its specific experimental condition. The
plate was cultured for an additional 24 h after replacing
the medium with a serum-free medium. Next, 20 μl
MTT solution (5 mg/ml) was added, and the plate was
incubated for 4 h at 37°C. The supernatant from eachFigure 1 Levels of ANX A1 mRNA and protein in PMVECs induced by
serum significantly decreased expression of the ANX A1 gene, including th
protein density of the ANX A1 gene for each group is displayed. Each data
* p < 0.05 vs. T1 or T2; # p < 0.05 vs. Group N. Group N: normal rat serum; Gwell was then carefully suctioned away and discarded. Fi-
nally, 150 μl DMSO was added to each well, and the
crystals were fully dissolved following 10 min of agita-
tion. The absorbance value of each well was measured
using an ELISA reader with 490 nm as the test wave-
length and 280 nm as the reference wavelength.
Statistical analysis
All data are expressed as the mean ± SEM. Comparisons
between groups were carried out using Student’s T
test or a Mann–Whitney U-test for parametric or
non-parametric tests, respectively. The results were
considered statistically significant when p < 0.05.
Results
CBDL rat serum decreased the transcript and protein
expression levels of ANX A1 in PMVECs
ANX A1 transcript and protein expression levels were
clearly detected in PMVECs of all groups. Following ex-
posure to CBDL-rat-serum, the ANX A1 transcript and
protein expression levels decreased persistently. There
were significant differences between the CBDL-rat-serum
group and normal-rat-serum group at T2 and T3 time
points (p < 0.05). This finding indicates that CBDL rat
serum down-regulates the expression level of the ANX A1
gene (Figure 1A, B and C).CBDL-Rat serum at each time point. (A.B) Exposure to CBDL-Rat
e transcript and protein levels in PMVECs (p < 0.05). (C) The mRNA and
point represents the mean ± S.E.M. of four independent experiments.
roup C: CBDL-Rat serum.
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genes were strongly expressed in PMVECs
PMVECs appeared to have a normal structure and no
pathological characteristics following transfection with a
60-MOI-dose of Ad-ANNXA1 for 24 h (Figure 2A).
After transfection with Ad-ANNXA1 containing green
fluorescent protein (GFP), cells were examined using an
inverted fluorescence microscope. Bright green fluores-
cence was observed in the cytoplasm and nuclei of
nearly all cells in the visual field (Figure 2B). At 24 h
post-transfection with Ad-ANNXA1, the staining of
ANNXA1 was easily observed in PMVECs after 12 h of
treatment with HPS-rat-serum (Figure 2C). At 24 h after
Ad-ANNXA1 transfection, a significant increase in both
transcript (p < 0.05) (Figure 2D) and protein levels ofFigure 2 Ad-ANXA1 transfected into PMVECs was strongly expressed
(A) At 24 h after transfection with Ad-ANXA1, PMVECs had a normal structu
100×). (B) Bright green fluorescence was observed in nearly all cells using a
Ad-ANXA1 containing the green fluorescent protein (GFP) gene (magnifica
PMVECs 24 h after either the mock transfection or transfection with Ad-AN
used as an internal control. (E) The mRNA and protein density of the ANX
mean ± S.E.M. of four independent experiments. * p < 0.05; N: Non-transfecANNXA1 (p < 0.05) (Figure 2E) was observed. These
findings demonstrate that over 95% of PMVECs were
successfully transfected with Ad-ANNXA1 and that the
genes encoded by Ad-ANNXA1 were effectively
expressed as proteins in the cytoplasm and nuclei of
PMVECs.
Over-expression of ANX A1 suppressed CBDL-rat-serum-
induced increase in the a1-actin, a1-tubulin and destrin
protein expression levels in PMVECs
Western blot analysis indicated that incubation in nor-
mal rat serum did not increase the a1-actin, a1-tubulin
and destrin protein expression levels, which remained
consistently low at each time point observed. Addition-
ally, there was no significant difference among each timeand the protein was found in both the cytoplasm and nuclei.
re with no observable pathological characteristics (magnification
n inverted fluorescence microscope following transfection with
tion 100×). (C.D) The expression of the ANX A1 mRNA and protein in
XA1 was determined by RT-PCR and western blotting. GAPDH was
A1 gene for each group is displayed. Each data point represents the
ted group; T: transfected group; E: empty vector group.
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CBDL rat serum significantly increased a1-actin, a1-
tubulin and destrin protein expression, and as the expos-
ure time increased, the expression of a1-actin, a1-tubulin
and destrin also increased (p < 0.05). After transfection of
Ad-ANXA1, the expression of a1-actin, a1-tubulin and
destrin induced by CBDL rat serum was inhibited signifi-
cantly at each time point (T2 an d T3) (Figure 3).
Over-expression of ANX A1 inhibited CBDL rat serum-
induced proliferation of PMVECs identified with 3H-TdR
incorporation assay and MTT assay
Under normal rat serum conditions, PMVECs ex-
hibited relatively low 3H-TdR incorporation. Following
exposure to CBDL rat serum, 3H-TdR incorporation in-
creased gradually as exposure time increased (p < 0.05).
CBDL rat serum enhanced rat PMVEC proliferation by
more than two-fold after 24 h of exposure in the non-
transfected (p < 0.05) and the empty vector groups. In-
corporation of 3H-TdR in the transfected group, however,
was significantly inhibited compared to the non-trans-
fected or the empty vector group. Differences in the in-
corporation of 3H-TdR were significant at each time point
measured (T1, T2, and T3) (p < 0.05) (Figure 4A).
The absorbance of MTT in each group increased grad-
ually as the exposure time to CBDL rat serum increased
(p < 0.05). The absorbance of MTT in the transfectedFigure 3 Over-expression of ANX A1 suppressed CBDL-rat-serum-indu
expression levels in PMVECs. (A) The change in expression levels of a1-a
mock transfection or transfection with Ad-ANXA1 was determined by west
density of a1-actin, a1-tubulin and destrin for each group is displayed. Each
experiments. * p < 0.05 vs. group N; # p < 0.05 vs. the non-transfected grougroup was significantly inhibited compared to both the
non-transfected and the empty vector group. Differences
in the absorbance of MTT were significant (p < 0.05) at
each time point measured (T1, T2, and T3) (Figure 4B).
Discussion
Liver cirrhosis and portal hypertension can result in pul-
monary vascular remodeling, which may involve changes
in cytokine signaling, leading to altered gene expression.
However, the cellular signaling mechanisms involved in
HPS–associated pulmonary vascular remodeling are still
poorly understood. Previous studies and our initial re-
search have demonstrated that the differentiation and
proliferation of PMVECs play an important role in the
pathogenesis of IPVD of HPS and that cytoskeletal
remodeling is the key change in the pathophysiolo-
gy of the proliferation or differentiation of PMVECs
[1,3,18,19]. Whether the regulation of cytoskeletal proteins
in PMVECs is a good therapeutic approach demands fur-
ther investigation. The major finding of this study is that
the ANX A1-mediated regulation of cytoskeletal protein
expression might play an important role in the prolifera-
tion of rat PMVECs induced by CBDL-Rat serum and that
ANX A1 might be one new therapeutic target for the de-
velopment of IPVD. The critical protein involved in the
development of HPS requires further research. Our work
is the first to demonstrate the role of ANX A1 andced increase in the a1-actin, a1-tubulin and destrin protein
ctin, a1-tubulin and destrin proteins in PMVECs 24 h following either
ern blot. GAPDH was used as an internal control. (B-D) The protein
data point represents the mean ± S.E.M. of four independent
p; Δp < 0.05 vs. T1. N: Non-transfected; T: transfected with Ad-ANXA1.
Figure 4 Over-expression of the ANXA1 gene inhibited CBDL-rat-serum-induced PMVEC proliferation as determined by the 3H-TdR and
MTT assay. (A.B) The change of the value of the incorporation of 3H-TdR and the absorbance of MTT assay is displayed. The inhibitory effect was
investigated at T2 and T3. Each data point represents the mean ± S.E.M. of four independent experiments. * P< 0.05 vs. group N; # P< 0.05 vs. Non-
transfected group and empty vector group. Non-N: Group N without Ad-ANXA1 transfection; Non-C: Group C without Ad-ANXA1 transfection; Empty-N:
Group N with empty vector transfection; Empty-C: Group C with empty vector transfection; Trans-N: Group N with Ad-ANXA1 transfection; Trans-C:
Group C with Ad-ANXA1 transfection.
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ation of PMVECs induced by CBDL-Rat serum.
Our previous study showed that CBDL-Rat serum in-
duced the proliferation and differentiation of PMVECs
[18,19]. The proliferation of PMVECs has been previously
shown to be accompanied by changes in cytoskeleton re-
modeling and cytoskeletal protein expression changes. Dy-
namic regulation of the cytoskeleton is critical for cell
motility, differentiation and proliferation due to a variety of
factors. During this process, actin stress fibers are first
depolymerized, and cortical actin is re-polymerized at the
leading edge of the cell. Our study showed that expression
of cytoskeletal proteins, including a1-actin, a1-tubulin and
destrin, in rat PMVECs was up-regulated significantly
under the CBDL-Rat serum condition. This result sug-
gested that CBDL-Rat serum could promote the cytoskel-
etal remodeling of PMVECs, which might be a key changeof PMVECs in IPVD. However, the detailed circumstances
and molecular mechanisms have not been defined.
Our data indicated that the expression of ANX A1 in
PMVECs decreased clearly under the CBDL-Rat serum
condition. Further, the over-expression of ANX A1 by
transfection of Ad-ANXA1 could reverse the prolifera-
tion of PMVECs induced by the CBDL-Rat serum. This
finding suggests that ANX A1 might play the role of an
inhibitor in the process of PMVEC proliferation. Further-
more, we found that the over-expression of ANX A1 by
transfection of Ad-ANXA1 reversed the up-regulation of
a1-actin, a1-tubulin and destrin in PMVECs induced by
CBDL-Rat serum. This finding suggests that ANX A1
might be an inhibitor during the process of PMVEC
differentiation.
Interestingly, we have reported that ANX A1 is acti-
vated during hypoxia-induced PASMC migration, which
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several cytoskeletal proteins, including SM-α-actin, MHC
and calponin, and cell migration in our initial study [22].
Thus, ANX A1 might be a key regulator of cytoskeleton
remodeling in PASMCs and PMVECs. Because both
PASMCs and PMVECs are involved in the pathogenesis
of IPVD, ANX A1 might be a more suitable therapeutic
target in HPS. However, more research is required.
Conclusion
In conclusion, our findings indicate that ANX A1 plays
an important regulatory role in cytoskeleton remodeling
of PMVECs in the pathogenesis of HPS. In the future, it
will be useful to understand the mechanisms of abnor-
mal cell proliferation and differentiation, as well as the
endogenous regulatory machinery in the cytokine sig-
naling cascade, to provide a basis for circumventing the
process and creating targeted therapies for diseases asso-
ciated with vascular remodeling in HPS.
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